Andrew Larry Frelinger III on Activation of Platelets in Flow Cytometry
Andrew Larry Frelinger III, Director Emeritus, Center for Platelet Research Studies Corresponding Faculty, Dept. of Pediatrics at Harvard Medical School, shared on LinkedIn:
”I am very pleased to share this publication which came about through a great collaboration with the Steve Watson lab.
The paper explores activation of GPVI, CLEC-2 and PEAR1 using multivalent nanobodies.
Special thanks to Rachel Lamerton for spearheading the work, Elenya Martin for preparing the nanobodies, and Jax Perry for the performing and analyzing the spectral cytometry assays.
These fantastic tools may aid in the development of assays to assess platelet function disorders.
Enjoy!”
Read the full article in RPTH.
Article: A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1
Authors: Rachel E. Lamerton, Eleyna M. Martin, Jacqueline Perry, Adam F. Cunningham, Steve P. Watson, Andrew Larry Frelinger III
Stay updated on all scientific advances with Hemostasis Today.
-
Dec 19, 2025, 13:30PPTA Europe’s Holiday Message: Wishing Health, Rest, and Renewal for 2026
-
Dec 19, 2025, 13:22If You Were Reading a “Bible for Blood Donation Volunteers,” What’s the ONE Thing That Must Be in It?
-
Dec 19, 2025, 12:52Julia Owens: Stroke Remains One of the World’s Leading Causes of Death and Disability
-
Dec 19, 2025, 12:03Pradeep Natarajan: Our New Genetic Study of Aortic Stenosis in ~3M
-
Dec 19, 2025, 11:47ESO Blog: Anna Gardin on Stroke Risk in the Era of Climate Extremes
-
Dec 19, 2025, 10:51Sarah Elkourashy Presents Insights on Caplacizumab for TTP at ASH25
-
Dec 19, 2025, 10:08Camilla Lombardi Shares an EHC Nutrition Guide for People with Bleeding Disorders
-
Dec 19, 2025, 09:56Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
-
Dec 19, 2025, 09:39Paul Bolaji: A Landmark Achievement -The Historic 1st Nigerian Stroke Leaders’ Summit 2025